Obesity & Weight Management in Primary Care: A Complete Clinical Framework

For decades, the clinical response to obesity was a variation of the same inadequate advice: eat less, move more. This approach failed not because patients lacked willpower, but because it fundamentally misunderstood the biology of obesity. We now know that obesity is a chronic, relapsing neurobiological disease driven by dysregulated appetite signalling, altered gut-brain communication, and a defended elevated body weight set-point. The hypothalamus actively defends fat mass through compensatory reductions in energy expenditure and increases in appetite hormones — a phenomenon called adaptive thermogenesis. This is why 95% of people who lose weight through caloric restriction alone regain it within 5 years. The clinical landscape has changed dramatically: the Edmonton Obesity Staging System provides a functional severity framework, and GLP-1 receptor agonists have achieved weight loss outcomes previously only seen with bariatric surgery. This guide gives GPs the tools to practise obesity medicine with the same rigour as any other chronic disease.

Reframing Obesity: Disease, Not Deficiency

The World Obesity Federation, Obesity Canada, and the European Association for the Study of Obesity all now formally classify obesity as a chronic disease. NICE guideline NG246 (2023) explicitly states that obesity should be managed as a long-term condition requiring ongoing support, not a one-time intervention. This reframing has profound clinical implications: it shifts the conversation from blame to biology, from willpower to neuroscience, and from short-term weight loss to long-term disease management. When a GP frames obesity as a disease in the consultation — "Your body is working against you here; this is a biological problem, not a personal failing" — it reduces shame, improves engagement, and increases treatment adherence.

The Edmonton Obesity Staging System (EOSS)

The Edmonton Obesity Staging System, developed by Dr. Arya Sharma and colleagues, is a 5-stage clinical staging tool that classifies obesity severity based on the presence and severity of obesity-related comorbidities, functional impairment, and psychological burden — not BMI. It is the most clinically meaningful obesity assessment tool available to GPs and is now endorsed by Obesity Canada and increasingly referenced in UK obesity guidelines. Critically, EOSS predicts mortality and treatment outcomes better than BMI alone: a patient with BMI 32 and EOSS Stage 3 has a higher mortality risk and greater treatment urgency than a patient with BMI 40 and EOSS Stage 0.

Assessment in Primary Care: Beyond the Scales

Anthropometric Measurements

• BMI: Calculate at every consultation; BMI ≥30 kg/m² = obesity; ≥35 = class II; ≥40 = class III (severe)
• Waist circumference: Measure at the midpoint between the lowest rib and iliac crest; high risk: ≥94 cm (men), ≥80 cm (women); very high risk: ≥102 cm (men), ≥88 cm (women)
• Waist:height ratio: >0.5 indicates central adiposity and elevated cardiometabolic risk — more sensitive than BMI alone
• Ethnicity adjustment: South Asian, Chinese, and Black African patients have higher cardiometabolic risk at lower BMI thresholds; use BMI ≥27.5 kg/m² as the intervention threshold in South Asian patients

Metabolic Investigations

Psychological and Functional Assessment

• Screen for depression and anxiety (PHQ-9, GAD-7) — present in 30–40% of patients with obesity seeking treatment
• Assess binge eating disorder (BED): "Do you ever eat a large amount of food in a short time and feel out of control?" — BED affects 5–10% of patients with obesity and requires specialist psychological input before pharmacotherapy or surgery
• Assess functional impairment: mobility, activities of daily living, employment, social participation
• Explore weight history: age of onset, triggers, previous weight loss attempts and outcomes, family history
• Assess readiness to change using the Stages of Change model — do not prescribe intensive intervention to a patient in the pre-contemplation stage

GLP-1 Receptor Agonists: The Weight Management Revolution

Glucagon-like peptide-1 (GLP-1) receptor agonists have transformed obesity pharmacotherapy. Originally developed as glucose-lowering agents for T2DM, higher-dose formulations have demonstrated weight loss outcomes that rival bariatric surgery in randomised controlled trials. The mechanism is multifaceted: GLP-1 agonists act on hypothalamic appetite centres to reduce hunger and increase satiety, slow gastric emptying to prolong fullness, and reduce the hedonic reward value of food. Crucially, they work with the biology of obesity rather than against it — they reduce the defended set-point rather than simply creating a caloric deficit that the body fights to reverse.

Semaglutide 2.4 mg (Wegovy) — The STEP Trials

Semaglutide 2.4 mg weekly (Wegovy) is the most extensively studied GLP-1 agonist for weight management. The STEP 1 trial (n=1,961, non-diabetic adults with BMI ≥30 or ≥27 with comorbidity) demonstrated mean weight loss of 14.9% at 68 weeks versus 2.4% with placebo. 69% of participants achieved ≥10% weight loss and 50% achieved ≥15% weight loss. The SELECT trial (2023) demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in patients with established CVD and obesity — the first weight management drug to demonstrate cardiovascular mortality benefit.

Tirzepatide (Mounjaro) — The SURMOUNT Trials

Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first in its class. By activating both GIP and GLP-1 receptors simultaneously, it produces greater appetite suppression and weight loss than GLP-1 agonism alone. The SURMOUNT-1 trial demonstrated mean weight loss of 20.9% at 72 weeks with tirzepatide 15 mg versus 3.1% with placebo — the largest weight loss ever demonstrated in a pharmacotherapy trial. 57% of participants achieved ≥20% weight loss. Tirzepatide is now licensed in the UK for weight management (Mounjaro) and is available on NHS for eligible patients.

Prescribing GLP-1 Agonists in Primary Care: Eligibility and Practical Points

• NICE NG246 eligibility for semaglutide/tirzepatide: BMI ≥35 kg/m² (or ≥30 kg/m² in South Asian/Black/other high-risk ethnic groups) with at least one weight-related comorbidity (T2DM, hypertension, dyslipidaemia, OSA, CVD)
• Prescribe as part of a specialist weight management service — GPs can continue prescriptions initiated by specialists
• Titration: Start at lowest dose and titrate monthly to minimise GI side effects (semaglutide: 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg over 16 weeks)
• Contraindications: Personal or family history of medullary thyroid carcinoma or MEN2 syndrome; pancreatitis history (relative); pregnancy
• Monitor: Weight monthly for first 6 months; HbA1c and BP at 3 and 6 months; review all diabetes medications (hypoglycaemia risk if on sulphonylurea/insulin)
• Discontinuation: If <5% weight loss at 6 months, reassess adherence and consider alternative agent or bariatric referral
• Weight regain on cessation: Weight regain of 60–70% of lost weight occurs within 1 year of stopping — frame as long-term treatment, not a short course

Bariatric Surgery: Who, When, and How to Refer

Bariatric surgery remains the most effective long-term treatment for severe obesity. It achieves mean excess weight loss of 60–80% at 2 years, T2DM remission in 50–80% of patients, and sustained cardiovascular risk reduction over 20+ years (Swedish Obese Subjects study). Despite this evidence, fewer than 1% of eligible patients in the UK undergo bariatric surgery, largely due to inadequate GP referral. Understanding the referral criteria and process is a core GP competency.

NICE Referral Criteria for Bariatric Surgery

Types of Bariatric Surgery: What GPs Need to Know

• Roux-en-Y Gastric Bypass (RYGB): Gold standard; 70–80% excess weight loss; T2DM remission in 80%; mechanism: restriction + malabsorption + gut hormone changes; lifelong vitamin supplementation required (B12, iron, calcium, vitamin D)
• Sleeve Gastrectomy: Most common procedure; 60–70% excess weight loss; restriction only (no malabsorption); lower complication rate; GORD may worsen — avoid in severe reflux
• Adjustable Gastric Band: Largely fallen out of favour; high long-term complication and revision rates; 40–50% excess weight loss
• One Anastomosis Gastric Bypass (OAGB/Mini-bypass): Increasingly popular; comparable outcomes to RYGB with shorter operative time; bile reflux risk
• Endoscopic procedures (intragastric balloon, endoscopic sleeve gastroplasty): Non-surgical options for BMI 30–40; 10–15% weight loss; temporary; useful bridge to surgery or for those unfit for surgery

Post-Bariatric Surgery: GP Monitoring Responsibilities

GPs play a critical role in long-term post-bariatric care. Nutritional deficiencies are common and potentially serious — particularly after RYGB and OAGB. All post-bariatric patients require lifelong nutritional supplementation and annual blood monitoring.

• Annual bloods: FBC, ferritin, B12, folate, calcium, vitamin D (25-OH), PTH, zinc, copper, selenium, thiamine
• Lifelong supplements: Multivitamin + mineral, calcium + vitamin D, B12 (sublingual or IM), iron (if menstruating or deficient)
• Dumping syndrome: Early (30 min post-meal) — nausea, flushing, palpitations, diarrhoea; Late (1–3 hours) — hypoglycaemia symptoms; manage with dietary modification (small frequent meals, avoid simple sugars)
• Medication review: Many medications require dose adjustment or formulation change post-surgery (avoid modified-release, enteric-coated, and NSAID formulations); review all medications at 3 months post-op
• Pregnancy: Advise contraception for 12–18 months post-surgery; nutritional monitoring essential in pregnancy after bariatric surgery
• Mental health: Suicide risk increases post-bariatric surgery — screen annually with PHQ-9; refer if concerns

The Obesity Consultation: A Practical Framework

Obesity consultations are among the most challenging in general practice — they carry significant emotional weight for patients who have often experienced years of stigma, failed attempts, and dismissive clinical encounters. The following framework, adapted from the 5As model (Ask, Assess, Advise, Agree, Assist), provides a structured approach that is both clinically effective and compassionate.

The 5As of Obesity Counselling

• Ask: "Would it be okay if we talked about your weight today?" — always seek permission; never raise weight unsolicited without a clinical reason
• Assess: BMI, waist circumference, EOSS staging, metabolic investigations, psychological screen, readiness to change
• Advise: Provide clear, non-judgmental information about health risks and treatment options — frame as biology, not behaviour: "Your body is defending a higher weight set-point; medication can help reset this"
• Agree: Collaboratively set a realistic goal — 5–10% weight loss as an initial target; agree on the treatment approach (lifestyle, pharmacotherapy, referral)
• Assist: Refer to structured weight management programme, prescribe pharmacotherapy if eligible, refer to bariatric surgery if criteria met, arrange follow-up

Structured Weight Management Programmes: NHS Referral Options

• NHS Tier 2 (community weight management): Group-based lifestyle programmes (12 weeks); available via GP referral; suitable for EOSS Stage 0–1; examples: Slimming World on Referral, Weight Watchers on Referral, local authority programmes
• NHS Tier 3 (specialist weight management): Multidisciplinary team (dietitian, psychologist, physician, physiotherapist); required before bariatric surgery referral; suitable for EOSS Stage 2–3; typically 6–12 months
• NHS Low Calorie Diet Programme: 800–900 kcal/day total diet replacement for 12 weeks; available for T2DM patients with BMI ≥27 (≥25 in South Asian patients); achieves 10–15 kg weight loss and T2DM remission in ~30–50%
• Digital programmes: NHS-approved apps (Second Nature, Oviva) provide structured dietary and behavioural support; accessible and scalable; suitable for motivated patients with EOSS Stage 0–1
• Social prescribing: Link workers can connect patients to community exercise groups, cooking classes, food banks, and peer support — address social determinants of obesity

Special Populations: Tailoring the Approach

Obesity in Pregnancy

Obesity in pregnancy (BMI ≥30) is associated with gestational diabetes, pre-eclampsia, macrosomia, caesarean section, and stillbirth. Weight loss is not recommended during pregnancy — the goal is gestational weight gain within recommended limits (5–9 kg for BMI ≥30). All pregnant women with obesity should be referred to a consultant-led antenatal clinic and receive aspirin 150 mg from 12 weeks (pre-eclampsia prevention). GLP-1 agonists are contraindicated in pregnancy — stop before conception.

Obesity in Older Adults

In adults aged ≥65 years, the relationship between BMI and mortality is attenuated — the "obesity paradox" means that modest overweight (BMI 25–30) may be protective in this age group. Weight loss in older adults carries a risk of sarcopenia (muscle loss), which worsens functional outcomes. Prioritise preservation of muscle mass through resistance exercise and adequate protein intake (≥1.2 g/kg/day) alongside any weight loss intervention. Avoid aggressive caloric restriction in frail older adults.

Obesity and Mental Health

The relationship between obesity and mental health is bidirectional and complex. Depression and anxiety increase the risk of obesity through emotional eating, reduced physical activity, and the metabolic effects of antidepressants (particularly mirtazapine, olanzapine, and quetiapine). Conversely, obesity increases the risk of depression through social stigma, functional impairment, and inflammatory cytokines. Always screen for and treat mental health comorbidities alongside obesity — untreated depression is the single strongest predictor of weight management treatment failure.